InvestorQ : What is your view on Gland Pharma after the latest quarterly results for Sep-21?
Mary Joseph made post

What is your view on Gland Pharma after the latest quarterly results for Sep-21?

Answer
image
Arusha Ray answered.
2 months ago
Follow

The core markets of US, Europe, Canada and Australia grew 25% to report revenues of Rs.665cr, while the revenues in the Indian market grew by 19% at Rs.184 crore. Rest of the world also registered healthy 59% growth at Rs.232 crore. Most of the growth in revenues was driven by new product launches.

Profit after tax for the Sep-21 quarter was up 38% yoy but lower by -13.85% on sequential basis due to input cost pressures. EBITDA surged 35% to Rs.428 crore yoy while EBITDA margin expanded from 37% to 38%. Gland had a healthy R&D outlay of Rs.58 crore which translates into 5.3% of total sales. Net margins at 27.96% were higher yoy.

Gland remains a niche play on the pharma space but the stock has rallied quite sharply although its profitable performance and growth remains a major positive.

4 Views